Benazepril Availability in 2026: A Provider Briefing

As a prescriber, you may have heard from patients who are struggling to fill their Benazepril prescriptions. While Benazepril is not currently listed on the FDA's Drug Shortage database, localized availability issues continue to affect patients across the country. This briefing provides an overview of the current landscape, prescribing implications, and practical tools to help your patients maintain their antihypertensive therapy.

Current Status and Timeline

Benazepril Hydrochloride (brand name Lotensin) is an ACE inhibitor FDA-approved for the treatment of hypertension. The Lotensin brand has been discontinued, but generic Benazepril remains widely manufactured by multiple companies including Amneal Pharmaceuticals, Aurobindo Pharma, Teva Pharmaceutical Industries, and Zydus Lifesciences.

As of Q1 2026:

• FDA shortage status: Not listed on the FDA Drug Shortages database
• Manufacturer status: Multiple active manufacturers with no reported production stoppages
• Supply chain: Generally stable, with intermittent localized disruptions reported at the pharmacy level
• Available strengths: 5 mg, 10 mg, 20 mg, and 40 mg oral tablets

Unlike medications that have experienced prolonged, systemwide shortages (such as certain stimulants and GLP-1 agonists), Benazepril's availability issues are primarily driven by distribution mechanics rather than fundamental supply deficits.

Prescribing Implications

When patients report difficulty filling Benazepril prescriptions, consider the following clinical and logistical factors:

Therapeutic Equivalence Within the ACE Inhibitor Class

All ACE inhibitors share the same mechanism of action — inhibition of angiotensin-converting enzyme — and provide similar blood pressure reduction. However, clinically meaningful differences exist:

• Hepatic metabolism: Benazepril is a prodrug metabolized in the liver to its active metabolite, benazeprilat. In patients with hepatic impairment, consider Lisinopril or Captopril, which are not hepatically metabolized.
• Renal dosing: For patients with CrCl <30 mL/min, the starting dose of Benazepril should be reduced to 5 mg daily (maximum 40 mg/day). Similar renal dose adjustments apply to other ACE inhibitors.
• Pediatric use: Benazepril is approved for hypertension in patients ≥6 years. Lisinopril and Enalapril also have pediatric indications and available liquid formulations.
• Cardiovascular outcomes data: Ramipril has particularly strong evidence from the HOPE trial for cardiovascular risk reduction in high-risk populations.

Switching Considerations

If switching a patient from Benazepril to another ACE inhibitor:

• There is no exact dose equivalence table for ACE inhibitors, but general guidance suggests moderate-dose Benazepril (20 mg) is roughly comparable to Lisinopril 10-20 mg, Enalapril 10-20 mg, or Ramipril 5-10 mg.
• Monitor blood pressure within 1-2 weeks after switching.
• Check serum creatinine and potassium within 1-2 weeks, particularly in patients with CKD or diabetes.
• If switching to an ARB (e.g., Losartan, Valsartan) due to ACE inhibitor intolerance, a washout period is not typically necessary, but monitor for hypotension.

Availability Picture

The distribution landscape for Benazepril in 2026 can be characterized as follows:

• Chain pharmacies: May experience intermittent stock-outs due to single-distributor contracts and allocation limits. CVS, Walgreens, and Rite Aid are most commonly affected.
• Independent pharmacies: Generally have better access through relationships with multiple wholesalers (McKesson, Cardinal Health, AmerisourceBergen, plus regional distributors).
• Mail-order pharmacies: Tend to maintain more consistent inventory. Express Scripts, OptumRx, Caremark, Amazon Pharmacy, and Cost Plus Drugs report stable supply.
• Combination products: Amlodipine/Benazepril (generic Lotrel) and Benazepril/HCTZ (generic Lotensin HCT) are widely available and may be appropriate for patients requiring combination therapy.

Cost and Access

Benazepril remains one of the most affordable antihypertensive medications available:

• Average retail price: $25-$30 for 30 tablets (without insurance)
• With discount coupons (GoodRx, SingleCare): $1.62-$7.56 for 30 tablets
• Insurance coverage: Covered as Tier 1 (preferred generic) on most commercial and Medicare Part D formularies, typically $0-$10 copay
• Prior authorization: Not typically required for generic Benazepril
• Step therapy: Not applicable for first-line antihypertensive use

For patients facing cost barriers, several resources are available:

• Pharmacy discount programs (GoodRx, SingleCare, RxSaver, BuzzRx)
• Walmart $4 generic prescription program
• Patient assistance through NeedyMeds and RxAssist for qualifying patients
• Cost Plus Drugs and Honeybee Health for transparent generic pricing

Tools and Resources for Your Practice

To help your patients find Benazepril and manage availability challenges, consider the following resources:

Medfinder for Providers

Medfinder offers a provider-facing tool that helps practices locate pharmacies with specific medications in stock. This can be integrated into your workflow to reduce call volume and improve patient satisfaction. When a patient reports difficulty filling a prescription, your staff can use Medfinder to identify nearby pharmacies with availability before the patient leaves your office.

Prescribing Best Practices

1. Prescribe generically: Writing "benazepril" rather than "Lotensin" ensures pharmacies can fill with any available manufacturer's product.
2. Consider 90-day prescriptions: This reduces the frequency of refills and gives patients a buffer against temporary stock-outs.
3. Document alternatives in the chart: If Benazepril is unavailable, having pre-discussed alternatives documented can speed up the switching process.
4. Use e-prescribing flexibility: Some EHR systems allow you to note acceptable therapeutic alternatives on the prescription, giving pharmacists more flexibility.
5. Educate patients: Direct patients to resources like medfinder.com so they can proactively check stock before going to the pharmacy.

Looking Ahead

The overall outlook for Benazepril availability in 2026 is positive. Multiple manufacturers remain active, the drug is not on the FDA shortage list, and pricing remains low. The intermittent availability issues patients experience are largely distribution-related rather than indicative of a systemic supply problem.

That said, the broader pharmaceutical supply chain remains fragile. Continued attention to prescribing practices, patient education, and proactive communication with pharmacies will help ensure your patients maintain uninterrupted access to their antihypertensive therapy.

Final Thoughts

Benazepril availability issues in 2026 are real but manageable. By understanding the distribution landscape, having switching protocols ready, and leveraging tools like Medfinder for Providers, you can minimize disruptions to your patients' care.

For additional clinical guidance, refer to the ACC/AHA 2017 Guidelines for the Management of High Blood Pressure in Adults and the current FDA prescribing information for Benazepril.

Related reading:

• How to Help Your Patients Find Benazepril in Stock: A Provider's Guide
• How to Help Patients Save Money on Benazepril: A Provider's Guide
• Alternatives to Benazepril If You Can't Fill Your Prescription